Turn Therapeutics (TTRX)
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technolo...
- Open
- 9.635
- High
- 9.925
- Low
- 9.350
- Prev. Close
- 9.540
- Volume
- 22.23K
- Turnover
- 212.90K
- Avg Price
- 9.579
- Bid/Ask Ratio
- --
- Amplitude
- 6.03%
- 52wk High
- 26.500
- Volume Ratio
- 0.19
- Turnover Ratio
- 0.20%
Turn Therapeutics Analyst Rating
View moreForecast & Rating
Aug 13, 2026Price forecast
$26.00174.84%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 20 at 07:03 AM
Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%
- PUBT · Aug 17 at 03:16 PM
Turn Therapeutics sells 135,000 shares in private placement for $1.35 million
- Tip Ranks · Aug 13 at 11:35 AM
Ladenburg Thalmann & Co. Keeps Their Buy Rating on Turn Therapeutics Inc (TTRX)
- Earnings Watch · Aug 12 at 04:23 PM
Turn Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
- PUBT · Jul 28 at 07:09 AM
Turn Therapeutics releases corporate deck outlining GX-03 topical immunomodulator program for atopic dermatitis
- PUBT · Jul 28 at 07:09 AM
Turn Therapeutics CEO to ring Nasdaq Closing Bell
